A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
Intravitreal complement inhibitor injections (IVCIs) for geographic atrophy appeared to be acceptable to most patients if they assumed the treatment had functional vision benefits, a cross-sectional ...
WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous ...
WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies ...
A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today ...
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more ...
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in progressive and irreversible vision loss, particularly in older adults. It occurs due to the ...
The approval and availability of Epioxa, a noninvasive, epithelium-on, oxygen-enriched treatment for keratoconus represents a ...
Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...
Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results